La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

ReShape Lifesciences Gestion

Gestion contrôle des critères 3/4

We currently do not have sufficient information about the CEO.

Informations clés

Paul Hickey

Directeur général

US$158.1k

Rémunération totale

Pourcentage du salaire du PDG	84.2%
Durée du mandat du directeur général	less than a year
Propriété du PDG	n/a
Durée moyenne d'occupation des postes de direction	less than a year
Durée moyenne du mandat des membres du conseil d'administration	4.6yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Paul Hickey a-t-elle évolué par rapport aux bénéfices de ReShape Lifesciences?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Sep 30 2022	n/a	n/a	-US$65m
Jun 30 2022	n/a	n/a	-US$71m
Mar 31 2022	n/a	n/a	-US$65m
Dec 31 2021	n/a	n/a	-US$62m
Sep 30 2021	n/a	n/a	-US$35m
Jun 30 2021	n/a	n/a	-US$22m
Mar 31 2021	n/a	n/a	-US$22m
Dec 31 2020	n/a	n/a	-US$22m
Sep 30 2020	n/a	n/a	-US$38m
Jun 30 2020	n/a	n/a	-US$62m
Mar 31 2020	n/a	n/a	-US$74m
Dec 31 2019	n/a	n/a	-US$74m
Sep 30 2019	n/a	n/a	-US$52m
Jun 30 2019	n/a	n/a	-US$28m
Mar 31 2019	n/a	n/a	-US$35m
Dec 31 2018	n/a	n/a	-US$38m
Sep 30 2018	n/a	n/a	-US$42m
Jun 30 2018	n/a	n/a	-US$47m
Mar 31 2018	n/a	n/a	-US$30m
Dec 31 2017	n/a	n/a	-US$30m
Sep 30 2017	n/a	n/a	-US$29m
Jun 30 2017	n/a	n/a	-US$25m
Mar 31 2017	n/a	n/a	-US$23m
Dec 31 2016	US$389k	US$278k	-US$23m

Rémunération vs marché: Paul's total compensation ($USD158.08K) is below average for companies of similar size in the German market ($USD418.12K).

Rémunération et revenus: Paul's compensation has been consistent with company performance over the past year.

PDG

Paul Hickey (57 yo)

less than a year

Titularisation

US$158,078

Compensation

Mr. Paul F. Hickey is Chief Executive Officer, President and Director at ReShape Lifesciences Inc. from August 15, 2022. He served as Senior Vice President of Marketing and Reimbursement at EnteroMedics In...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Dan Gladney	Executive Chair	7.2yrs	US$95.26k	0.17% $ 6.1k
Paul Hickey	CEO, President & Director	less than a year	US$158.08k	pas de données
Thomas Stankovich	Chief Financial Officer	3.3yrs	US$555.84k	1.28% $ 44.7k
Mark Knudson	Co-Founder and Special Advisor to the CEO	no data	US$2.45m	pas de données
Katherine Tweden	Co-Founder	no data	US$400.95k	pas de données
Al Diaz	Vice President of Operations and R&D	1.4yrs	pas de données	pas de données
Dov Gal	VP of Regulatory Clinical Quality & Compliance Officer	no data	pas de données	pas de données
Jody Dahlman	Director of Communications	no data	pas de données	pas de données
Naqeeb Ansari	Senior Vice President of Global Commercial Operations	less than a year	US$1.16m	pas de données

0.5yrs

Durée moyenne de l'emploi

61yo

Âge moyen

Gestion expérimentée: 24O's management team is not considered experienced ( 0.5 years average tenure), which suggests a new team.

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Dan Gladney	Executive Chair	7.2yrs	US$95.26k	0.17% $ 6.1k
Paul Hickey	CEO, President & Director	less than a year	US$158.08k	pas de données
Gary Blackford	Independent Lead Director	6.4yrs	US$77.00k	0% $ 0
Philip Schauer	Member of Scientific Advisory Board	4.6yrs	pas de données	pas de données
Scott Shikora	Member of Scientific Advisory Board	4.6yrs	US$892.19k	pas de données
Lori McDougal	Independent Director	7.5yrs	US$57.50k	0% $ 0
Jaime Ponce	Member of Scientific Advisory Board	4.6yrs	pas de données	pas de données
John Morton	Member of Scientific Advisory Board	4.6yrs	pas de données	pas de données
Natan Zundel	Member of Scientific Advisory Board	4.6yrs	pas de données	pas de données
Arda Minocherhomjee	Independent Director	4.4yrs	US$52.50k	pas de données

4.6yrs

Durée moyenne de l'emploi

64yo

Âge moyen

Conseil d'administration expérimenté: 24O's board of directors are considered experienced (4.6 years average tenure).

ReShape Lifesciences Gestion

Gestion contrôle des critères 3/4

Informations clés

Mises à jour récentes de la gestion

ReShape Lifesciences Inc., Annual General Meeting, Feb 23, 2024

ReShape Lifesciences Inc., Annual General Meeting, Dec 14, 2022

Reshape Lifesciences Inc. Appoints Nick Ansari, as Senior Vice President of Global Commercial Operations

Insufficient new directors

ReShape Lifesciences Appoints Paul F. Hickey as Chief Executive Officer, Effective August 15, 2022

High number of new directors

Recent updates

ReShape Lifesciences Inc. to Report Q2, 2024 Results on Aug 14, 2024

ReShape Lifesciences Inc. to Report Q1, 2024 Results on May 15, 2024

The Nasdaq Stock Market Determines ReShape Lifesciences Eligible for an Additional 180 Calendar Period, or Until October 7, 2024, to Regain Compliance with Minimum Bid Price Requirement

ReShape Lifesciences Receives Notice of Allowance for Additional U.S. Patent Related to Intragastric Balloon System

Reshape Lifesciences® Announces First Surgeries Utilizing Next-Generation Lap-Band 2.0 Flex

ReShape Lifesciences Inc., Annual General Meeting, Feb 23, 2024

ReShape Lifesciences Inc. to Report Q3, 2023 Results on Nov 08, 2023

ReShape Lifesciences Receives Non-Compliance Notice From Nasdaq

ReShape Lifesciences Receives NIH SBIR Grant to Further Develop Proprietary Diabetes Bloc-Stim Neuromodulation Device

ReShape Lifesciences Inc. to Report Q2, 2023 Results on Aug 07, 2023

ReShape Lifesciences Inc. Presents Data on its Proprietary Diabetes Bloc-Stim Neuromodulation(TM) Device at the ASMBS 2023 Annual Meeting

ReShape Lifesciences Submits FDA PMA Supplement Application for the Next-Generation Lap-Band® 2.0

ReShape Lifesciences Inc. to Report Q1, 2023 Results on May 15, 2023

ReShape Lifesciences Inc. has completed a Composite Units Offering in the amount of $10.2 million.

ReShape Lifesciences Inc. has completed a Composite Units Offering in the amount of $10.2 million.

Third quarter 2022 earnings released: US$0.60 loss per share (vs US$1.48 loss in 3Q 2021)

ReShape Lifesciences Inc. Provides Revenue Guidance

ReShape Lifesciences Inc., Annual General Meeting, Dec 14, 2022

ReShape Lifesciences Inc. to Report Q3, 2022 Results on Nov 14, 2022

Reshape Lifesciences™ Announces That the ASMBS and IFSO Have Issued Updated Guidelines on Indications for Metabolic and Bariatric Surgery, Including the Lap-Band®

ReShape Lifesciences Announces Release of Positive Consensus Statement on Lap-Band Use and Lap-Band Aftercare Management by American Society of Metabolic and Bariatric Surgery

Reshape Lifesciences Inc. Appoints Nick Ansari, as Senior Vice President of Global Commercial Operations

ReShape Lifesciences Inc. announced delayed 10-Q filing

Insufficient new directors

Reshape Lifesciences™ Receives FDA 510(K) Clearance for the Gibi Hd™ Calibration Tubes for Use in Gastric and Bariatric Procedures

ReShape Lifesciences Appoints Paul F. Hickey as Chief Executive Officer, Effective August 15, 2022

ReShape Lifesciences Receives Non-Compliance Notice from Nasdaq

ReShape Lifesciences Inc. to Report Q1, 2022 Results on May 23, 2022

ReShape Lifesciences Inc. announced delayed 10-Q filing

ReShape Lifesciences Inc. announced delayed annual 10-K filing

Full year 2021 earnings released: US$5.00 loss per share (vs US$3.12 loss in FY 2020)

Third quarter 2021 earnings released: US$1.48 loss per share (vs US$0.74 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.47 loss per share (vs US$0.52 loss in 2Q 2020)

High number of new directors

Analyse de la rémunération des PDG

PDG

Titularisation

Compensation

Équipe de direction

Durée moyenne de l'emploi

Âge moyen

Membres du conseil d'administration

Durée moyenne de l'emploi

Âge moyen